Kyntra Bio Inc (NASDAQ:KYNB) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $32.50.

Several analysts recently commented on the company. Rodman & Renshaw began coverage on Kyntra Bio in a report on Tuesday, June 9th. They issued a “buy” rating and a $30.00 price objective for the company. Weiss Ratings raised Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 14th. Finally, Oppenheimer assumed coverage on Kyntra Bio in a research report on Monday, July 6th. They issued an “outperform” rating and a $35.00 target price on the stock.

Hedge Funds Weigh In On Kyntra Bio

An institutional investor recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC acquired a new position in Kyntra Bio Inc (NASDAQ:KYNB) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio at the end of the most recent quarter. 72.71% of the stock is currently owned by institutional investors and hedge funds.

Kyntra Bio Trading Up 6.1%

Shares of KYNB opened at $7.98 on Tuesday. The firm has a fifty day simple moving average of $7.15 and a two-hundred day simple moving average of $7.13. The firm has a market cap of $32.32 million, a PE ratio of 0.18 and a beta of 1.02. Kyntra Bio has a 1-year low of $6.32 and a 1-year high of $12.60.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.